Isogenica: Improving peptides

Although the possibility of using peptides as therapeutics is attractive, they still have disadvantages versus antibodies and small molecules. Isogenica Ltd. believes its Cis-display technology can improve the therapeutic properties of peptides, making them at least as attractive as monoclonal antibodies.

Compared to antibodies, peptides have lower production costs, greater stability and better interaction with the biologically

Read the full 564 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE